News - pomalidomide

Filter

Current filters:

pomalidomide

Popular Filters

Pomalidomide Celgene OKed in Europe

09-08-2013

The European Commission has granted approval for US biotech firm Celgene's (Nasdaq: CELG) Pomalidomide…

BiotechnologyCelgeneEuropeImnovidOncologypomalidomidePomalidomide CelgeneRegulation

FDA approves Celgene's Pomalyst for advanced multiple myeloma

11-02-2013

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Pomalyst…

BiotechnologyCelgeneNorth AmericaOncologypomalidomidePomalystRegulation

Celgene's pomalidomide meets MM-003 study endpoints

23-10-2012

US biotech firm Celgene's (Nasdaq: CELG) European subsidiary yesterday revealed that its phase III, multi-center,…

BiotechnologyCelgeneOncologypomalidomideResearch

VentiRx collaborates with Celgene on cancer drug candidate; pomalidomide update

05-10-2012

VentiRx Pharmaceuticals, a privately held US biopharmaceutical company dedicated to the development of…

BiotechnologyCelgeneLicensingNorth AmericaOncologyPharmaceuticalpomalidomideRegulationVentiRx PharmaceuticalsVTX-2337

Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine

21-09-2012

US biotech firm Celgene (Nasdaq: CELG) says that the US Food and Drug Administration's Oncologic Drugs…

Asia-PacificBiotechnologyCelgeneLundbeckNeurologicalNorth AmericaOncologyPharmaceuticalpomalidomideRegulationvortioxetine

Celgene slumps as it pulls new EU indication filing for Revlimid

22-06-2012

Celgene International, the European subsidiary of USA-based Celgene Corp (Nasdaq: CELG), has provided…

BiotechnologyCelgeneEuropeFinancialOncologyPharmaceuticalpomalidomideRegulationRevlimid

Company Spotlight

Fibrotech

Fibrotech

Back to top